

08-02-01

A  
Box/seqjc62 U.S. PTO  
08/01/01

Certificate of Mailing	
Date of Deposit <u>August 1, 2001</u>	Label Number: <u>EL790829755US</u>
<p>I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.</p>	
<u>Guy Beardsley</u> Printed name of person mailing correspondence	<u>Guy Beardsley</u> Signature of person mailing correspondence

1C872 U.S. PTO  
09/01/01

### UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 C.F.R. § 1.53(b)

Attorney Docket Number	50125/015002
Applicant	Eckhard Wolf et al.
Title	POLYPEPTIDES OR NUCLEIC ACIDS ENCODING THESE OF A FAMILY OF G-PROTEIN COUPLED RECEPTORS AND THEIR USE FOR THE DIAGNOSIS OR TREATMENT OF DISORDERS, FOR EXAMPLE SKIN DISORDERS AND THEIR USE FOR THE IDENTIFICATION OF PHARMACOLOGICALLY ACTIVE SUBSTANCES

#### PRIORITY INFORMATION:



This application claims the benefit of the filing date of United States provisional patent application 60/229,501, filed August 31, 2000, and foreign patent application DE 10038111.1, filed August 4, 2000, in Germany.

#### SMALL ENTITY STATUS:

Applicant claims small entity status under 37 C.F.R. § 1.27.

#### APPLICATION ELEMENTS:

Cover sheet	1 page
Specification	52 pages
Claims	6 pages
Abstract	1 page
Drawing	7 sheets
Combined Declaration and POA, which is: <input checked="" type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input type="checkbox"/> A copy from prior application [**SERIAL NUMBER**] and the entire disclosure of the prior application is considered as being part of the disclosure of this new application and is hereby incorporated by reference therein.	3 pages
Sequence Statement	2 pages
Sequence Listing on Paper	15 pages
Sequence Listing on Diskette	one disk

Small Entity Statement, which is: <input type="checkbox"/> A copy from prior application [**SERIAL NUMBER**] and such small entity status is still proper and desired.	
Preliminary Amendment	
IDS	
Form PTO 1449	
Cited References	
Recordation Form Cover Sheet and Assignment	
English Translation	
Certified Copy of Priority Document	
Return Receipt Postcard	1
<b>FILING FEES:</b>	
Basic Filing Fee: \$355	\$355.00
Excess Claims Fee: 50 - 20 x \$9	\$270.00
Excess Independent Claims Fee: 5 - 3 x \$40	\$80.00
Multiple Dependent Claims Fee: \$135	\$135.00
Total Fees:	\$840.00
<input checked="" type="checkbox"/> Enclosed is a check for \$840.00 to cover the total fees. <input checked="" type="checkbox"/> Please apply any other charges, or any credits, to Deposit Account No. 03-2095.	
<b>CORRESPONDENCE ADDRESS:</b>	
Karen L. Elbing, Ph.D. Reg. No. 35,238 Clark & Elbing LLP 176 Federal Street Boston, MA 02110	
Telephone: 617-428-0200 Facsimile: 617-428-7045	
<b>CUSTOMER NO: 21559</b>	
 Signature	
 Date	

\Clark-w2k1\documents\50125\50125.015002 Utility Transmittal.wpd



21559

PATENT TRADEMARK OFFICE

PATENT  
ATTORNEY DOCKET NUMBER: 50125/015002

Certificate of Mailing


Date of Deposit August 1, 2001

Label Number: EL790829755US

I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Guy Beardsley

Printed name of person mailing correspondence



Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Eckhard Wolf et al.	Art Unit:
Serial No.:	Not yet assigned	Examiner:
Filed:	August 1, 2001	Customer No.: 21559
Title:	POLYPEPTIDES OR NUCLEIC ACIDS ENCODING THESE OF A FAMILY OF G-PROTEIN COUPLED RECEPTORS AND THEIR USE FOR THE DIAGNOSIS OR TREATMENT OF DISORDERS, FOR EXAMPLE SKIN DISORDERS AND THEIR USE FOR THE IDENTIFICATION OF PHARMACOLOGICALLY ACTIVE SUBSTANCES	

Assistant Commissioner For Patents  
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a sequence listing in accordance with the requirements of 37 C.F.R. §§ 1.821 through 1.825 and consisting of 15 pages.

As required by 37 C.F.R. § 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing.

And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 1 August 2001

  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

  
21559  
PATENT TRADEMARK OFFICE